Bidirectional regulatory roles of COMMD1 in tumorigenesis and progression: Translational prospects as a diagnostic and therapeutic target (Review)

Copper metabolism MURR1 domain‑containing protein 1 (COMMD1) is one of the best‑characterised members of the COMMD protein family. Initially identified as a key regulator of copper ion homeostasis, accumulating evidence has shown that COMMD1 does not function as a canonical tumour suppressor or oncogene in malignant tumours. Instead, it serves as a context‑dependent molecular hub whose activity is dynamically influenced by cellular background, signalling pathway status and post‑translational modifications. On the one hand, COMMD1 exerts antitumour effects by inhibiting NF‑κB and hypoxia‑inducible factor‑1 signalling, regulating DNA damage repair, modulating cell cycle progression and enhancing apoptotic sensitivity. Conversely, in certain tumour types, COMMD1 may promote drug resistance and adaptive tumour evolution by preserving DNA repair capacity, supporting cell survival or modulating ubiquitination networks. This review systematically summarises the differential expression patterns and functional mechanisms of COMMD1 in lung cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, multiple myeloma, neuroblastoma and breast cancer, with particular emphasis on its pivotal roles in the inflammatory immune microenvironment, hypoxic adaptation, genomic stability and drug sensitivity. Furthermore, translational strategies targeting COMMD1 are discussed, including COMMD1‑dependent peptide therapeutics, small‑molecule stabilisers, copper chelation‑based combination therapies and gene regulatory interventions. Collectively, the evidence supports COMMD1 as a potential integrated diagnostic and therapeutic target in precision oncology. However, its tissue‑specific and bidirectional functions highlight the need for further mechanistic investigation and patient stratification to enable precise clinical translation.

Authors

Institutions

Publication Details

Journal
Oncology Reports
Published
2026-11-18
DOI
https://doi.org/10.3892/or.2026.9224
Primary Topic
Cancer-related Molecular Pathways
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Bidirectional regulatory roles of COMMD1 in tumorigenesis and progression: Translational prospects as a diagnostic and therapeutic target (Review)

俞柳敏, Jinqiu Li, Rui Shi, Wei Lin et al.
2 links
Oncology Reports
Cancer-related Molecular Pathways
article

Bidirectional regulatory roles of COMMD1 in tumorigenesis and progression: Translational prospects as a diagnostic and therapeutic target (Review)

俞柳敏, Jinqiu Li, Rui Shi, Wei Lin, Xiaojie Jiang, Kehao Huang, Zhonghui Chen
article en

Abstract

Copper metabolism MURR1 domain‑containing protein 1 (COMMD1) is one of the best‑characterised members of the COMMD protein family. Initially identified as a key regulator of copper ion homeostasis, accumulating evidence has shown that COMMD1 does not function as a canonical tumour suppressor or oncogene in malignant tumours. Instead, it serves as a context‑dependent molecular hub whose activity is dynamically influenced by cellular background, signalling pathway status and post‑translational modifications. On the one hand, COMMD1 exerts antitumour effects by inhibiting NF‑κB and hypoxia‑inducible factor‑1 signalling, regulating DNA damage repair, modulating cell cycle progression and enhancing apoptotic sensitivity. Conversely, in certain tumour types, COMMD1 may promote drug resistance and adaptive tumour evolution by preserving DNA repair capacity, supporting cell survival or modulating ubiquitination networks. This review systematically summarises the differential expression patterns and functional mechanisms of COMMD1 in lung cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, multiple myeloma, neuroblastoma and breast cancer, with particular emphasis on its pivotal roles in the inflammatory immune microenvironment, hypoxic adaptation, genomic stability and drug sensitivity. Furthermore, translational strategies targeting COMMD1 are discussed, including COMMD1‑dependent peptide therapeutics, small‑molecule stabilisers, copper chelation‑based combination therapies and gene regulatory interventions. Collectively, the evidence supports COMMD1 as a potential integrated diagnostic and therapeutic target in precision oncology. However, its tissue‑specific and bidirectional functions highlight the need for further mechanistic investigation and patient stratification to enable precise clinical translation.

Oncology ReportsVol. 57(1)
Putian University (CN)
Natural Science Foundation of Fujian Province, Putian University
Good health and well-being
Cancer-related Molecular Pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon